Literature DB >> 11276125

Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.

M Onuki1, M M Ayers, C C Bernard, J M Orian.   

Abstract

Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS), characterised by focal destruction of myelin. Although it is evident that the immune system contributes to tissue destruction in MS, it is still unclear as to whether this immune response is a cause or a consequence of the disease process. In addition, there is debate over the contribution of axonal damage to clinical progression. We have described a murine model of relapsing-remitting MS (RR-MS), the most common form of the disease, following immunisation with the myelin component, myelin oligodendrocyte glycoprotein (MOG). We showed that a single injection of a MOG peptide (MOG(35-55)) in NOD/Lt mice induces a paralytic relapsing disease with extensive plaque-like demyelination. This model also mimics many of the immunological features associated with RR-MS. To investigate the relationship between clinical episodes, inflammation, and demyelination/remyelination, we analysed lesions during each attack and remission over the course of the disease, using histological, immunocytochemical, and electron microscopy (EM) techniques. We show that morphological features of lesions in our model resemble those observed in MS. Indeed, severe inflammation and demyelination coincide with the peak of clinical episodes while remissions are characterised by quiescent plaques. Furthermore, axonal damage is evident from the earliest stage of the disease and increases in severity with subsequent relapses. These data establish that in the model of MS-like disease, the peak of clinical episodes coincides with severe inflammation and demyelination and that axonal pathology correlates with clinical progression. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11276125     DOI: 10.1002/jemt.1057

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  13 in total

1.  Silencing Nogo-A promotes functional recovery in demyelinating disease.

Authors:  Yuhong Yang; Yue Liu; Ping Wei; Haiyan Peng; Ryan Winger; Rehana Z Hussain; Li-Hong Ben; Petra D Cravens; Anne R Gocke; Krishna Puttaparthi; Michael K Racke; Dana M McTigue; Amy E Lovett-Racke
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis.

Authors:  Rieko Muramatsu; Takekazu Kubo; Masahiro Mori; Yuka Nakamura; Yuki Fujita; Tsugio Akutsu; Tatsusada Okuno; Junko Taniguchi; Atsushi Kumanogoh; Mari Yoshida; Hideki Mochizuki; Satoshi Kuwabara; Toshihide Yamashita
Journal:  Nat Med       Date:  2011-03-20       Impact factor: 53.440

3.  Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination.

Authors:  Jae Young Lee; Min Joung Kim; Speros Thomas; Viola Oorschot; Georg Ramm; Pei Mun Aui; Yuichi Sekine; Devy Deliyanti; Jennifer Wilkinson-Berka; Be'eri Niego; Alan R Harvey; Paschalis Theotokis; Catriona McLean; Stephen M Strittmatter; Steven Petratos
Journal:  J Neurosci       Date:  2019-05-06       Impact factor: 6.167

Review 4.  Multiple sclerosis and regulatory T cells.

Authors:  Cristina Maria Costantino; Clare Baecher-Allan; David A Hafler
Journal:  J Clin Immunol       Date:  2008-09-02       Impact factor: 8.317

5.  Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.

Authors:  T Komiya; K Sato; H Shioya; Y Inagaki; H Hagiya; R Kozaki; M Imai; Y Takada; T Maeda; H Kurata; M Kurono; R Suzuki; K Otsuki; H Habashita; S Nakade
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

6.  MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors:  Peizhong Mao; Maria Manczak; Ulziibat P Shirendeb; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2013-09-19

7.  Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity.

Authors:  Ulf Schulze-Topphoff; Simona Casazza; Michel Varrin-Doyer; Kara Pekarek; Raymond A Sobel; Stephen L Hauser; Jorge R Oksenberg; Scott S Zamvil; Sergio E Baranzini
Journal:  J Exp Med       Date:  2013-07-01       Impact factor: 14.307

8.  Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice.

Authors:  Kirk Pak; Sic L Chan; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 4.103

9.  Effect of aqueous extract of Achillea millefolium on the development of experimental autoimmune encephalomyelitis in C57BL/6 mice.

Authors:  Reza Vazirinejad; Fateme Ayoobi; Mohammad Kazemi Arababadi; Mohammad M Eftekharian; Ali Darekordi; Mahdi Goudarzvand; Gholamhossein Hassanshahi; Mohammad Mohsen Taghavi; Behzad Nasiri Ahmadabadi; Derek Kennedy; Ali Shamsizadeh
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

10.  Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis.

Authors:  Conan K Wang; Christian W Gruber; Maša Cemazar; Christopher Siatskas; Prascilla Tagore; Natalie Payne; Guizhi Sun; Shunhe Wang; Claude C Bernard; David J Craik
Journal:  ACS Chem Biol       Date:  2013-11-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.